Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus


Colesevelam has been suggested as a promising alternative treatment for patients with type 2 diabetes mellitus (T2DM) who are intolerant to statins or who have an elevated LDL cholesterol level despite statin treatment. In this Practice Point commentary, we discuss a randomized, controlled, double-blind trial that assessed the effect of colesevelam treatment on glycemic control in patients with T2DM that was not adequately controlled by insulin alone or by insulin and oral hypoglycemic agents. After 16 weeks, colesevelam improved glycemic control and decreased LDL cholesterol levels, but it increased triglyceride levels. The occurrence of hypoglycemia and weight gain was not affected by colesevelam treatment. The beneficial effects of colesevelam on both glucose and LDL cholesterol levels suggest that this agent provides a useful treatment option for patients with T2DM. Nevertheless, the risk of poor compliance with colesevelam treatment in clinical practice, the high treatment cost and the lack of outcome data are limitations to the wider use of this drug.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. Florentin M et al. (2008) Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr Med Res Opin 24: 995–1009

    Article  CAS  PubMed  Google Scholar 

  2. Goldberg RB et al. (2008) Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 168: 1531–1540

    Article  CAS  PubMed  Google Scholar 

  3. Fonseca VA et al. (2008) Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31: 1479–1484

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Davidson MH (2007) The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother 8: 2569–2578

    Article  CAS  PubMed  Google Scholar 

  5. Sarwar N et al. (2007) Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115: 450–458

    Article  CAS  PubMed  Google Scholar 

  6. Bays HE and Goldberg RB (2007) The 'forgotten' bile acid sequestrants: is now a good time to remember. Am J Ther 14: 567–580

    Article  PubMed  Google Scholar 

Download references


K Tziomalos is supported by a grant from the Hellenic Atherosclerosis Society.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Dimitri P Mikhailidis.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tziomalos, K., Athyros, V. & Mikhailidis, D. Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. Nat Rev Endocrinol 5, 16–17 (2009).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing